The Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) Guidelines: An international Delphi consensus study
Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman
Research Square November 18, 2024 preprint DOI: 10.21203/rs.3.rs-5428217/v1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Delphi consensus study |
|---|---|
| Sample size | 89 |
| Population | International group of psychedelic researchers, clinicians, and past trial participants |
| Keywords | Delphi method Clinical trial Medical physics Artificial intelligence |
| Citations | 2 |
| Key points | Thirty extra-pharmacological variables reached consensus as important or very important for reporting, forming the ReSPCT guidelines for psychedelic clinical trials. |
Abstract
Abstract Background Psychedelic substances exhibit complex interactions with the ‘set and setting’ of use, i.e., the internal state of the user and the external environment in which a psychedelic experience takes place. Despite the known importance of these contextual variables, psychedelic research has suffered from methodological weaknesses in reporting extra-pharmacological factors and from a lack of consensus regarding their relative importance.
Methods: The study aimed to generate consensus-based guidelines for the reporting of settings in psychedelic clinical research, according to a diverse international group of psychedelic researchers, clinicians, and past trial participants. We conducted a large international Delphi consensus study composed of four iterative rounds of quasi-anonymous online surveys and facilitated debates.
Findings: Eighty-nine experts from 17 countries initially identified hundreds of potentially important psychedelic setting variables. These 770 responses were synthesized into 49 distinct items that were then rated, debated, and refined in subsequent rounds. The process resulted in 30 extra-pharmacological variables reaching pre-defined consensus thresholds: rated “important” or “very important” for reporting by at least 70% of experts. These items compose the Reporting of Setting in Psychedelic Clinical Trials (ReSPCT) guidelines, categorized into: physical environment, dosing session procedure, therapeutic framework and protocol, and subjective experiences. Emergent study findings reveal significant ambiguities in current conceptualizations of set and setting.
Interpretation: The ReSPCT guidelines and its accompanying explanatory document provide a new standard for the design and documentation of extra-pharmacological variables in psychedelic clinical research. Drug-context interactions warrant further attention to ensure the methodological rigor of psychedelic research.
Funding: Societal Engagement Seed Fund, Imperial College London.
Citations in the library
Cites 19
- Constructing drug effects: A history of set and setting Drug Science, Policy and Law 2017
- Prediction of Psilocybin Response in Healthy Volunteers PLoS One February 17, 2012
- Blinding and expectancy confounds in psychedelic randomized controlled trials Expert Review of Clinical Pharmacology May 26, 2021
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
- Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development Frontiers in Pharmacology July 5, 2018
and 14 more in the library